| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 869,50 | 869,60 | 15:29 | |
| 0,000 | 0,000 | 15:29 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 878,70 | 12 | |||
| 878,60 | 24 | |||
| 878,10 | 100 | |||
| 877,90 | 50 | |||
| 875,90 | 40 | |||
| 875,70 | 9 | |||
| 875,60 | 9 | |||
| 875,40 | 25 | |||
| 875,30 | 23 | |||
| 875,20 | 7 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/lly.htm [/URL] | ||||
| 6 | 873,50 | |||
| 32 | 873,40 | |||
| 40 | 873,30 | |||
| 80 | 873,00 | |||
| 20 | 872,90 | |||
| 20 | 871,90 | |||
| 30 | 871,80 | |||
| 100 | 871,70 | |||
| 50 | 871,00 | |||
| 10 | 870,00 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 388 | 0,771 | 299 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:02:01 | 873,70 | 25 |
| 14:20:54 | 872,50 | 9 |
| 14:18:01 | 872,70 | 40 |
| 14:10:34 | 873,20 | 5 |
| 13:39:28 | 872,70 | 1 |
| 13:02:00 | 872,90 | 11 |
| 12:56:33 | 872,00 | 5 |
| 12:17:58 | 872,10 | 1 |
| 12:00:28 | 872,90 | 10 |
| 11:59:48 | 873,90 | 2 |
| 11:34:30 | 873,40 | 4 |
| 11:33:14 | 873,60 | 1 |
| 11:06:07 | 876,40 | 4 |
| 10:19:31 | 872,90 | 1 |
| 10:03:00 | 872,10 | 9 |
| 09:04:56 | 874,40 | 2 |
| 09:04:56 | 873,00 | 4 |
| Tagesumsatz Xetra | -6,60 -0,75 % | 267 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:59 | Lilly says orforglipron tops Wegovy pill in diabetes trial | 27 | pharmaphorum | ||
| ELI LILLY Aktie jetzt für 0€ handeln | |||||
| 14:10 | Diabetes-Studie: Orales Medikament von Eli Lilly übertrifft Semaglutid | 7 | Investing.com Deutsch | ||
| 13:36 | Lilly's Orforglipron Outperforms Semaglutide In Blood Sugar And Weight Reduction In Phase 3 Study | 194 | AFX News | INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) on Thursday reported positive results from its Phase 3 ACHIEVE-3 trial evaluating orforglipron in adults with type 2 diabetes inadequately... ► Artikel lesen | |
| Mi | Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. | 7 | The Motley Fool | ||
| Mi | Bernstein reiterates Eli Lilly stock rating after Novo pricing move | 74 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 11:10 | Novo Nordisk-Aktie: Kurssturz auf unter 30 Euro möglich | sharedeals.de | Die Aktie von Novo Nordisk galt lange als Inbegriff eines sicheren Wachstumsinvestments und als einer der größten Gewinner des globalen Pharma-Booms. Doch nach einer Serie enttäuschender Nachrichten... ► Artikel lesen | |
| 10:00 | Hikma Pharma FY25 Earnings Rise; Launches $250 Mln Buyback, Guides FY26; Shares Plunge | AFX News | LONDON (dpa-AFX) - Hikma Pharmaceuticals PLC (HIK.L), on Thursday reported higher profit for the full year 2025, driven by revenue growth and improved core performance.For the full year 2025... ► Artikel lesen | |
| 09:54 | GSK's NDA For Bepirovirsen Accepted In Japan For Chronic Hepatitis B | AFX News | LONDON (dpa-AFX) - GSK plc (GSK) on Thursday said Japan's Ministry of Health, Labour and Welfare has accepted a new drug application for bepirovirsen for the treatment of adults with chronic... ► Artikel lesen | |
| 12:36 | Compass Pathfinder Limited: Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants | Business Wire | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of 35,059,448 warrants, which were... ► Artikel lesen | |
| 13:10 | Boehringer Ingelheim Limited: Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics | GlobeNewswire (Europe) | The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cellsDeal includes upfront and milestone payments... ► Artikel lesen |